Merck & Co. Inc. diskutieren
Merck & Co. Inc.
WKN: A0YD8Q / Symbol: MRK / Name: Merck & Co / Aktie / Pharmazeutika / Large Cap /
127,76 €
-1,81 %
Merck & Co., Inc. (MRK) had its price target raised by Bank of America Corporation from $130.00 to $141.00. They now have a "buy" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (MRK) had its "outperform" rating reaffirmed by Royal Bank Of Canada. They now have a $142.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (MRK) had its price target raised by Guggenheim from $140.00 to $145.00. They now have a "buy" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (MRK) had its price target raised by BMO Capital Markets from $135.00 to $142.00. They now have an "outperform" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (MRK) had its price target raised by JPMorgan Chase & Co. from $135.00 to $140.00. They now have an "overweight" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (MRK) had its price target raised by Barclays PLC from $140.00 to $150.00. They now have an "overweight" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (MRK) had its price target raised by Guggenheim from $145.00 to $146.00. They now have a "buy" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (MRK) had its price target raised by Argus from $130.00 to $145.00. They now have a "buy" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (MRK) was upgraded by Daiwa Securities Group Inc. from "neutral" to "outperform". They now have a $143.00 price target on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (MRK) was upgraded by Morgan Stanley from "equal weight" to "overweight". They now have a $179.00 price target on the stock, up from $116.00.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (MRK) had its price target raised by UBS Group AG from $145.00 to $175.00. They now have a "buy" rating on the stock.
Ratings data for MRK provided by MarketBeat
Merck & Co., Inc. (MRK) had its price target raised by BMO Capital Markets from $142.00 to $170.00. They now have an "outperform" rating on the stock.
Ratings data for MRK provided by MarketBeat
Neueste Beiträge
Canaccord_Genuity_Gr in Ultragenyx Pharmaceutical Inc. diskutieren